The Worthy Worm

Therapy Weekly, September 2002

By David Potterton (extracts)

Serrapeptase is said to digest non-living tissue such as blood clots, cysts and arterial plaque and to block the inflammatory process. There is a story of a young woman who suffered back pain for six years as the result of a motorcycle accident. But after taking Serrapeptase for only 10 days her pain disappeared.

Apart from sports injuries and other causes of pain, the enzyme is being heralded as a treatment for conditions such as arthritis, fibromyalgia, chronic obstructive pulmonary disease, inflammatory bowel disease and even multiple sclerosis.

Serrapeptase has been used in Asia and the Far East for over 25 years.

A controlled trial in Germany studied the effect of Serrapeptase on ankle swelling caused by trauma. The study involved 66 patients treated surgically for rupture of the lateral ligament. They were randomized into three groups, one of which received Serrapeptase.

In the group receiving the test substance postoperative swelling had decreased by 50% by the third postoperative day. In the other two groups (who had leg elevation and bed rest with and without the application of ice) no reduction in swelling had occurred at that time. (Editor’s Note: The study also included carpal tunnel syndrome patients.)

Italian microbiologists say that biofilm formation is one of the most widespread mechanisms of bacterial resistance and a common cause of treatment failure in prosthetic device infections. They made various attempts to develop ways of inhibiting these biofilm-embedded bacteria. They found in seven different experiments that Serrapeptase greatly enhanced antibiotic activity and inhibited biofilm formation.

The ability of Serrapeptase to remove mucous in conditions such as emphysema, Bronchiectasis [(pronounced bron-kee-ek’-tas-is) is a disorder of the airways within the lungs] and bronchitis may also be of interest. A team at the University of Naples evaluated the efficacy and tolerability of Serrapeptase in a multi center, double blind, placebo controlled study of 193 subjects suffering from acute or chronic ear nose or throat disorders. After three or four days significant symptom regression was observed in the Serrapeptase treated patients as compared to placebo.